2025 Archives - Page 2 of 7

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2025 (Price sensitive)

Sep 23, 2025 | 2025, Investors, Press Releases

more details

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation

Sep 23, 2025 | 2025, Investors, Press Releases

more details

Philogen to attend the European Society of Nuclear Medicine (EANM) annual meeting on October 4 – 8, 2025

Sep 2, 2025 | 2025, Past Events

Dr. Samuele Cazzamalli is presenting “From DNA-encoded chemistry to ACP3-targeted radioligand therapeutics against prostate cancer”. In addition, Dr. Cristiano Pini will give an update on “Diagnostic Performance, Safety, and Pharmacokinetics of [68Ga]Ga-OncoACP3 in...

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

Aug 18, 2025 | 2025, Investors, Press Releases

For more details

La controllata Philochem AG annuncia il completamento del processo autorizzativo antitrust e la conclusione dell’accordo di licenza OncoACP3 con RayzeBio, una società di Bristol Myers Squibb, con un valore potenziale fino a 1,35 miliardi di dollari più royalties.

Aug 18, 2025 | 2025, Investors, Press Releases

Per maggiori dettagli

Philogen to attend the Biopharma and Life Sciences Private Event in London (UK) on November 18, 2025

Aug 4, 2025 | 2025, Events, Investors

Prof. Dario Neri will participate to the event, which will convene a distinguished community of executives, investors and thought leaders in BioPharma and Life Sciences.

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2025 (Price sensitive)

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation

Philogen to attend the European Society of Nuclear Medicine (EANM) annual meeting on October 4 – 8, 2025

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

La controllata Philochem AG annuncia il completamento del processo autorizzativo antitrust e la conclusione dell’accordo di licenza OncoACP3 con RayzeBio, una società di Bristol Myers Squibb, con un valore potenziale fino a 1,35 miliardi di dollari più royalties.

Philogen to attend the Biopharma and Life Sciences Private Event in London (UK) on November 18, 2025

Recent Posts

Recent Comments

Legal